MX2019008603A - Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer. - Google Patents

Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.

Info

Publication number
MX2019008603A
MX2019008603A MX2019008603A MX2019008603A MX2019008603A MX 2019008603 A MX2019008603 A MX 2019008603A MX 2019008603 A MX2019008603 A MX 2019008603A MX 2019008603 A MX2019008603 A MX 2019008603A MX 2019008603 A MX2019008603 A MX 2019008603A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
prevention
treatment
pharmaceutical composition
Prior art date
Application number
MX2019008603A
Other languages
English (en)
Inventor
Ramos Rita
Knezic Dragutin
Achour Miloud
Galli Bruno
John Edgar
Juhnke Michael
Shamji Koraida Vishal
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019008603A publication Critical patent/MX2019008603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está relacionada con una composición farmacéutica que comprende un derivado de oxazina inhibidor de BACE-1, un proceso para su preparación, y su uso en el tratamiento o la prevención de la enfermedad de Alzheimer.
MX2019008603A 2017-01-20 2018-01-18 Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer. MX2019008603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17152481 2017-01-20
PCT/IB2018/050312 WO2018134760A1 (en) 2017-01-20 2018-01-18 A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2019008603A true MX2019008603A (es) 2019-09-10

Family

ID=57890668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008603A MX2019008603A (es) 2017-01-20 2018-01-18 Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MX2019008601A MX2019008601A (es) 2017-01-20 2018-01-18 Un derivado de oxazina base libre en forma cristalina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008601A MX2019008601A (es) 2017-01-20 2018-01-18 Un derivado de oxazina base libre en forma cristalina.

Country Status (21)

Country Link
US (2) US20200048237A1 (es)
EP (2) EP3571195A1 (es)
JP (2) JP2020505363A (es)
KR (1) KR20190126291A (es)
CN (1) CN110167535A (es)
AR (1) AR110758A1 (es)
AU (3) AU2018209442A1 (es)
BR (2) BR112019014825A2 (es)
CA (2) CA3048346A1 (es)
CL (1) CL2019002020A1 (es)
CO (2) CO2019007671A2 (es)
CR (1) CR20190333A (es)
IL (2) IL267640A (es)
JO (2) JOP20190178A1 (es)
MX (2) MX2019008603A (es)
PE (2) PE20191250A1 (es)
RU (1) RU2019126022A (es)
SG (2) SG11201905116PA (es)
TW (1) TW201828943A (es)
UY (1) UY37572A (es)
WO (2) WO2018134760A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019142111A1 (en) * 2018-01-18 2019-07-25 Novartis Ag Salt forms of an oxazine derivative bace inhibitor
CN112661667B (zh) * 2020-12-28 2023-02-03 浦拉司科技（上海）有限责任公司 一种三氟乙脒的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3807A (en) 2011-01-13 2016-09-30 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
JOP20190178A1 (ar) 2019-07-16
KR20190126291A (ko) 2019-11-11
SG11201905116PA (en) 2019-08-27
AU2018209442A1 (en) 2019-06-20
EP3570820A1 (en) 2019-11-27
IL267640A (en) 2019-08-29
CA3048346A1 (en) 2018-07-26
US20200048237A1 (en) 2020-02-13
RU2019126022A (ru) 2021-02-20
CO2019007670A2 (es) 2019-07-31
RU2019126022A3 (es) 2021-10-19
TW201828943A (zh) 2018-08-16
BR112019014234A2 (pt) 2020-03-17
WO2018134761A1 (en) 2018-07-26
US20190388428A1 (en) 2019-12-26
CO2019007671A2 (es) 2019-07-31
EP3571195A1 (en) 2019-11-27
AU2018208870A1 (en) 2019-07-04
PE20191250A1 (es) 2019-09-18
CA3046304A1 (en) 2018-07-26
CL2019002020A1 (es) 2019-10-04
JP2020505363A (ja) 2020-02-20
SG11201905528XA (en) 2019-08-27
JP2020505367A (ja) 2020-02-20
UY37572A (es) 2018-08-31
MX2019008601A (es) 2019-09-10
AU2020289738A1 (en) 2021-01-21
BR112019014825A2 (pt) 2020-02-27
PE20191346A1 (es) 2019-09-30
CR20190333A (es) 2019-09-13
WO2018134760A1 (en) 2018-07-26
JOP20190180A1 (ar) 2019-07-20
CN110167535A (zh) 2019-08-23
AR110758A1 (es) 2019-05-02
IL268131A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2016109217A3 (en) Btk inhibitors
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
PH12017501668A1 (en) Bace1 inhibitors
MX2016008968A (es) Compuestos organicos.
EP3616704A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S MORBUS WITH GINSENG EXTRACT FROM MOUNTAIN FARMING
EP3610879A4 (en) COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.